SCHEMBL30011050

SCHEMBL30011050

CN(C)C1CCN(c2ccc(-c3ccc4ncn5c(c(C6CCOCC6)c(=O)n5C)c4c3)cc2C(F)(F)F)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTOR P42345 11/20 0.41
▸ ATM Q13315 4/20 0.41
▸ ATR Q13535 3/20 0.41
▸ PIK3CA P42336 2/20 0.41
▸ PDE3B Q13370 3/20 0.38
▸ PDE3A Q14432 3/20 0.38
▸ FLT3 P36888 1/20 0.38
▸ SYK P43405 1/20 0.38
▸ AURKB Q96GD4 1/20 0.38
▸ NOTUM Q6P988 1/20 0.37
▸ PIK3CD O00329 1/20 0.36
▸ CSNK2A2 P19784 1/20 0.36
▸ FECH P22830 1/20 0.36
▸ PIK3CB P42338 1/20 0.36
▸ PIK3CG P48736 1/20 0.36
▸ CLK1 P49759 1/20 0.36
▸ GSK3A P49840 1/20 0.36
▸ DYRK1A Q13627 1/20 0.36
▸ MELK Q14680 1/20 0.36
▸ MYLK3 Q32MK0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30012169 0.92 MTOR (0.41) MTORATMATRPIK3CAPDE3B
SCHEMBL30011461 0.91 ATM (0.42) MTORATMATRPIK3CAPDE3B
SCHEMBL30012789 0.90 MTOR (0.40) MTORPIK3CAPDE3BPDE3AFLT3
SCHEMBL30012532 0.90 ATM (0.41) MTORATMATRPIK3CASYK
SCHEMBL30839640 0.90 ATM (0.41) MTORATMATRPIK3CASYK
SCHEMBL30012579 0.88 MTOR (0.39) MTORPIK3CAPDE3BPDE3AFLT3
SCHEMBL30012567 0.85 MTOR (0.45) MTORATMATRPIK3CAPIK3CD
SCHEMBL29217578 0.85 MTOR (0.45) MTORATMATRPIK3CAPIK3CD
SCHEMBL30013129 0.80 ATM (0.47) MTORATMATRPIK3CAPIK3CD
SCHEMBL30012314 0.77 ATM (0.48) MTORATMATRPIK3CASYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114026097-B Substituted pyrazoloquinazolinone compounds and uses thereof 上海瑛派药业有限公司 2024-02-23 — — CN claimed
US-20220259211-A1 SUBSTITUTED PYRAZOLOQUINAZOLINONE COMPOUNDS AND APPLICATION THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2022-08-18 — — US claimed
CN-114026097-B Substituted pyrazoloquinazolinone compounds and uses thereof 上海瑛派药业有限公司 2024-02-23 — — CN disclosed
US-20220259211-A1 SUBSTITUTED PYRAZOLOQUINAZOLINONE COMPOUNDS AND APPLICATION THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2022-08-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220259211-A1 SUBSTITUTED PYRAZOLOQUINAZOLINONE COMPOUNDS AND APPLICATION THEREOF CHEK1, CHEK2, ATM MTOR 283/4885ATM 3/4885ATR 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback